Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ono/Seikagaku’s Novel Osteoarthritis Drug Hits Primary Goal in Japan PIII
Ono Pharmaceutical/Seikagaku’s novel osteoarthritis therapy ONO-5704/SI-613 met the primary endpoint in a PIII confirmatory study conducted in Japan for the treatment of knee osteoarthritis, according to topline data released by the two companies on February 19. In the PIII study,…
To read the full story
Related Article
- Ono, Seikagaku File Novel Osteoarthritis Treatment in Japan
January 7, 2020
- SI-613 Enters PIIb Study for Enthesopathy: Ono, Seikagaku
October 3, 2017
- Seikagaku, Ono Ink Definitive Deal on Osteoarthritis Treatment
September 4, 2017
- Seikagaku, Ono to Link Up on Osteoarthritis Treatment
May 16, 2017
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Specialist Hails Wegovy as “Game Changer” for MASH Treatment
July 1, 2026
- Alfresa Boosts Stake in ENT Cell Sheet Startup
July 1, 2026
- Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…